1N40C5-1-US

 1N40C5-2-US

 1N40C5-4-US

 1N40C5-5-US

 1N40C5-8-US

1N40C5-10-US

1N40C5-20-US

1N40C5-40-US

Rapid SARS-CoV-2 

Antigen Test Card

USER INSTRUCTIONS

A rapid test for the detection of SARS-CoV-2 antigens in anterior 

nasal specimens. 

For Emergency Use Authorization (EUA) use only.

In vitro diagnostic use only.

• For more information on EUAs visit: https://www.fda.gov/

emergency-preparedness-and-response/mcm-legal-regulatory-andpolicy-framework/emergency-use-authorization

• For the most up to date information on COVID-19, please visit: 

www.cdc.gov/COVID19

Kit Contents

Test Cassette in

sealed pouch

Buffer tube

Swab in 

sealed 

Needed but not provided: pouch

clock or timer Tube holder

Storage and Stability

Store the kit at 2-30°C / 36-86°F and protect from direct 

sunlight. The expiration date of the materials is indicated 

on the external packaging. Do not freeze the kit. Do not 

use kit past its expiration date. For information about 

current expiration dates for at-home OTC COVID-19 

diagnostic tests, visit http://www.fda.gov/covid-tests.

Preparation

1. Wash your hands with soap and water, 

or use hand sanitizer,before performing 

the test.

2. Check test expiration date on the test cassette pouch. 

3. Bring the kit to room temperature when you are 

ready to begin the test.

Note

A nasal swab sample can be self-collected by an 

individual aged 14 years and older. Children aged 

2 to 13 years should be tested by an adult. 

Test Procedure

4. When you are ready to perform 

the test, remove the seal from 

the buffer tube and place the 

tube in the tube holder. 

Open it away from 

your face and be 

careful not to spill 

any of the liquid.

5. Peel open the swab packaging 

and gently take out the swab. 

Be careful not to touch the 

soft, fabric tip of the swab.

6. Holding the stick end of the swab, 

gently insert the entire absorbent 

tip of the swab into the nostril no 

more than 1⁄2 to 3⁄4 inch. There is 

no need to go deeper.

Slowly rotate the swab in a 

circular motion 5 times by 

firmly pressing against the 

inside walls of the nostril 

for a total of 15 seconds. 

Do not just spin the swab.

Gently remove the swab 

and repeat in the other 

nostril using the same swab. 

WARNING: Inaccurate test results may 

occur if the nasal swab specimen is not 

properly collected.

When swabbing others, please wear a face mask. 

With children, you may not need to insert the swab 

as far into the nostril. For very young children, you 

may need another person to hold the child’s head 

while swabbing.

7. Place swab 

into buffer tube.

Rotate swab 

5 times.

Set a timer and 

leave swab in 

buffer tube for 

1 minute.

8. Pinch buffer tube with fingers 

and remove the 

solution from swab as much 

as possible. 

WARNING: Failure to 

squeeze the tube can lead 

to incorrect results due to 

excess buffer in the swab.

9. Press the cap onto the buffer 

tube until it is secure.

10. Open the pouch and remove the test cassette. 

Place the cassette on a flat and level surface.

WARNING: Once 

opened, the test 

cassette must be 

used within 30 

minutes, otherwise 

inaccurate results 

may occur.

11. Invert the buffer tube and add 

3 drops of test sample into the 

sample well (S) by gently 

squeezing the extraction tube. 

Do not add test sample to the 

rectangular results window.

WARNING: Adding other 

than the recommended 

number of drops may result 

in inaccurate results.

12. Set a timer and read the results at 15 minutes.

WARNING: Do not read the result before 

15 minutes or after 30 minutes. 

After test is completed, dispose of used

materials in trash.

Read and Interpret the Results

WARNING: Do not read the result before 15 minutes or after 

30 minutes. Inaccurate test interpretations may occur.

Look at the result window and locate the letters C and T on the side of 

the window. A pink/purple line should always appear at the C position; 

this is a control line and signals that the test is working properly.

< Negative result

If the Control (C) line is visible, but the Test (T) line 

is not visible, the test is negative. To increase the 

chance that the negative result for COVID-19 is 

accurate, you should:

• Test again in 48 hours if you have symptoms on the first day 

of testing.

• Test 2 more times at least 48 hours apart if you do not have 

symptoms on the first day of testing.

A negative test result indicates that the virus that causes COVID-19 was 

not detected in your sample. A negative result is presumptive, meaning 

it is not certain that you do not have COVID-19. You may still have 

COVID-19 and you may still be contagious. There is a higher chance of 

false negative results with antigen tests compared to laboratory-based 

tests such as PCR. If you test negative and continue to experience 

COVID-19-like symptoms, (e.g., fever, cough, and/or shortness of breath) 

you should seek follow up care with your health care provider.

< Positive result

If the Control (C) line and the Test (T) line are visible, 

the test is positive. Any faint visible test (T) line with 

the control line (C) should be read as positive. You 

do not need to perform repeat testing if you 

have a positive result at any time. A positive test result means that 

the virus that causes COVID-19 was detected in your sample and it is 

very likely you have COVID-19 and are contagious. Please contact your 

doctor/primary care physician or your local health authority immediately 

and adhere to the local guidelines regarding self-isolation. There is a very 

small chance that this test can give a positive result that is incorrect (a 

false positive).

< Invalid result

If the control (C) line is not visible, the test is invalid. 

Re-test with a new swab and new test device.
Read and Interpret the Results (Cont’d)

Repeat testing is needed to improve test accuracy. Please follow the table below when interpreting test results for COVID-19. 

Status on First Day 

of Testing

First Result

Day 1

Second Result 

Day 3

Third Result

Day 5 Interpretation

With Symptoms

Positive N/A N/A Positive for COVID-19

Negative Positive N/A Positive for COVID-19

Negative Negative N/A Negative for COVID-19

Without Symptoms

Positive N/A N/A Positive for COVID-19

Negative Positive N/A Positive for COVID-19

Negative Negative Positive Positive for COVID-19

Negative Negative Negative Negative for COVID-19

Results should be considered in the context of an individual’s recent exposures, history, and the presence of clinical signs 

and symptoms consistent with COVID-19.

To report your test result, please go to www.bosoncov.com and follow the instructions

How to Use this Test

• Serial testing should be performed in all individuals with negative results; individuals with symptoms of COVID-19 

and initial negative results should be tested again after 48 hours. Individuals without symptoms of COVID-19, and 

with initial negative results, should be tested again after 48 hours and, if the 2nd test is also negative, a 3rd time 

after an additional 48 hours. You may need to purchase additional tests to perform this serial (repeat) testing.

• If you test negative but continue to have symptoms of COVID-19, and both your first and second tests are negative, 

you may not have COVID-19, however you should follow-up with your healthcare provider.

• If your test is positive, then proteins from the virus that causes COVID-19 have been found in your sample and you 

likely have COVID-19.

Intended Use

The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of 

nucleocapsid protein antigen from SARS-CoV-2.This test is authorized for non-prescription home use with selfcollected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal 

(nares) swab samples from individual aged two years or older. This test is authorized for individuals with symptoms of 

COVID-19 within the first 6 days of symptom onset when tested at least twice over three days with at least 48 hours 

between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when 

tested at least three times over five days with at least 48 hours between tests.

The Rapid SARS-CoV-2 Antigen Test Card does not differentiate between SARS-CoV and SARS-CoV-2. 

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in 

anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, 

but clinical correlation with past medical history and other diagnostic information is necessary to determine infection 

status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not 

be the definite cause of disease. Individuals who test positive with the Rapid COVID-19 Antigen Test Card should selfisolate and seek follow up care with their physician or healthcare provider as additional testing may be necessary.

All negative results should be treated as presumptive and confirmation with a molecular assay, if necessary for patient 

management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the 

sole basis for treatment or patient management decisions, including infection control measures such as isolating from 

others and wearing masks. 

Negative results should be considered in the context of an individual’s recent exposures, history and the presence of 

clinical signs and symptoms consistent with COVID-19.

Individuals who test negative and continue to experience COVID-like symptoms of fever, cough and/or shortness of 

breath may still have SARS-CoV-2 infection and should seek follow up care from their healthcare provider.

Individuals should provide all results obtained with this product to their healthcare provider for public health reporting. 

All healthcare providers will report all test results they receive from individuals who use the authorized product to 

relevant public health authorities in accordance with local, state, and federal requirements using appropriate LOINC 

and SNOMED codes, as defined by the Laboratory In Vitro Diagnostics (LIVD) Test Code Mapping for SARS-CoV-2 

Tests provided by CDC.

The Rapid SARS-CoV-2 Antigen Test Card is authorized for non-prescription self-use and/or as applicable an adult lay 

user testing another person 2 years or older in a non-laboratory setting.

The Rapid SARS-CoV-2 Antigen Test Card is only for use under the Food and Drug Administration’s Emergency Use 

Authorization. This product has not been FDA cleared or approved.

Warnings, Precautions, and Safety Information

• Read all instructions carefully before performing the test. Failure to follow the instructions may result in inaccurate 

test results.

• In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency 

Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any 

other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that 

circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis 

of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless 

the declaration is terminated or authorization is revoked sooner.

• Serial testing should be performed in individuals with negative results at least twice over three days (with 48 hours 

between tests) for symptomatic individuals and three times over five days (with at least 48 hours between tests) for 

asymptomatic individuals. You may need to purchase additional tests to perform this serial (repeat) testing.

• If you have had symptoms longer than 6 days you should consider testing at least three times over five days with at 

least 48 hours between tests.

• An anterior nasal swab sample can be self-collected by an individual age 14 years and older. Children age 2 to 13 years 

should be tested by an adult.

• Do not use on anyone under 2 years of age.

• Wear a safety mask or other face-covering when collecting a specimen from a child or another individual.

• Do not use if any of the test kit contents or packaging is damaged.

• Test components are single-use. Do not re-use.

• Do not use kit past its expiration date.

• Do not touch the swab tip.

• Once opened, the test card should be used within 30 minutes.

• Do not read test results before 15 minutes or after 30 minutes. Results read before 15 minutes or after 30 minutes may 

lead to a false positive, false negative, or invalid result.

• If applicable: Keep testing kit and kit components away from children and pets before and after use. Avoid contact with 

your skin, eyes, nose, or mouth. Do not ingest any kit components. The reagent solution contains harmful chemicals 

(see table below). If the solution contacts your skin, eyes, nose, or mouth, flush with large amounts of water. 

If irritation persists, seek medical advice: https://www.poisonhelp.org or 1-800-222-1222. 

Hazard Category 

(mixture)

GHS Hazard Class for 

mixture

Labeling of Harm(s) Hazardous 

Ingredients (%)

Recommended 

PPE Statement

Category 2/2A Eye Irritation Causes serious eye 

irritation (H319)

Sodium chloride 

7647-14-5/1%

TERGITOL 

15-S-9/1%

Wear eye 

protection

Category 3 Skin Irritation Causes mild skin 

irritation (H316)

TERGITOL 

15-S-9/1%

NA

• For more information on EUAs please visit: https://www.fda.gov/emergency-preparedness-and-response/

mcm-legal-regulatory-and-policy-framework/emergency-use-authorization 

• For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19

Limitations

• There is a higher chance of false negative results with antigen tests than with laboratory-based molecular tests due to 

the sensitivity of the test technology. This means that there is a higher chance this test will give a false negative result 

in an individual with COVID-19 as compared to a molecular test, especially in samples with low viral load.

• The performance of this test was established based on the evaluation of a limited number of clinical specimens 

collected between January 2022 and February 2022. The clinical performance has not been established for all 

circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of 

the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including 

newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

• All COVID-19 antigen test negative results are presumptive and confirmation with a molecular assay may be 

necessary. If you continue to have symptoms of COVID-19, and both your first and second tests are negative, you 

may not have COVID-19, however you should follow-up with a healthcare provider. 

• If the test is positive, then proteins from the virus that causes COVID-19 have been found in the sample and you likely 

have COVID-19.

• This test is read visually and has not been validated for use by those with impaired vision or color-impaired vision. 

• Incorrect test results may occur if a specimen is incorrectly collected or handled.

Frequently Asked Questions

WHAT ARE THE KNOWN AND POTENTIAL RISKS AND BENEFITS OF THE TEST?

Potential risks include:

• Possible discomfort during sample collection.

• Possible incorrect test result (see Warnings and Result Interpretation sections for more information).

Potential benefits include:

• The results, along with other information, can help you and your healthcare provider make informed recommendations 

about your care.

Frequently Asked Questions (Cont’d)

• The results of this test may help limit the potential spread of COVID-19 to your family and others in your community.

For more information on EUAs go here: https://www.fda.gov/emergency-preparedness-and-response/

mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

WHAT IS THE DIFFERENCE BETWEEN AN ANTIGEN AND MOLECULAR TEST?

There are different kinds of tests for the SARS-CoV-2 virus that causes COVID-19. Molecular tests detect genetic 

material from the virus. Antigen tests, such as the Rapid SARS-CoV-2 Antigen Home Test, detect proteins from the 

virus. Due to the lower sensitivity of antigen tests, there is a higher chance this test will give you a false negative result 

when you have COVID-19 than a molecular test would. 

HOW ACCURATE IS THIS TEST?

Clinical studies have shown that antigen tests more accurately determine whether you are infected with the virus that 

causes COVID-19 when taken multiple times across several days. Repeat testing improves test accuracy. This serial 

testing approach is recommended to minimize the risk of incorrect results. For more information on the performance of 

the test and how the performance may apply to you, please refer to the performance data in the Healthcare Provider 

Instructions for Use (IFU), available at www.bosoncovt.com. 

WHAT IF I HAVE A POSITIVE TEST RESULT?

A positive result means that it is very likely you have COVID-19 because proteins from the virus that causes COVID-19 

were found in your sample. You should self-isolate from others and contact a healthcare provider for medical advice 

about your positive result. 

WHAT IF I HAVE A NEGATIVE TEST RESULT?

A negative test result indicates that antigens from the virus that causes COVID-19 were not detected in your sample. 

However, if you have symptoms of COVID-19, and your first test is negative, you should test again in 48 hours since 

antigen tests are not as sensitive as molecular tests. If you do not have symptoms and received a negative result, 

you should test at least two more times with 48 hours in between tests for a total of three tests. If you have a negative 

result, it does not rule out SARS-CoV-2 infection; you may still be infected and you may still infect others. It is important 

that you work with your healthcare provider to help you understand the next steps you should take.

WHAT DOES AN INVALID TEST RESULT MEAN?

An invalid result means the test was not able to tell if you have COVID-19 or not. If the test is invalid, a new swab 

should be used to collect a new nasal specimen and you should test again with a new test.

IMPORTANT

Do not use this test as the only guide to manage your illness. Consult your healthcare provider if your symptoms persist 

or become more severe. Individuals should provide all results obtained with this product to their healthcare provider.

Index of Symbols

Manufacturer Date of manufacture

Contains sufficient for <n> tests Catalogue number

In vitro diagnostic medical device Use-by date

Consult instructions for use Batch code

Store between 2-30°C / 36-86°F Do not reuse

Materials Provided

Components 1 Test

per Box

2 Tests

per Box

4 Tests

per Box

5 Tests

per Box

8 Tests

per Box

10 Tests

per Box

20 Tests

per Box

40 Tests

per Box

Rapid SARS-CoV-2 

Antigen Test Card 1 2 4 5 8 10 20 40

Sterilized Swab 1 2 4 5 8 10 20 40

Extraction Buffer 

Tube 1 2 4 5 8 10 20 40

Tube Holder 1 

(packaging)

1 

(packaging)

1 1 2 2 5 5

Quick Reference 

Instructions 1 1 1 1 2 2 5 5

Xiamen Boson Biotech Co., Ltd.

90-94 Tianfeng Road, Jimei North 

Industrial Park Xiamen, Fujian, 361021, 

P.R. China.

Tel: +1-800-689-7794 

Email: support@bosoncovt.com

www.bosoncovt.com

Number: 082316 Effective Date: 2022-12
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 minutes For Use Under an Emergency Use Authorization (EUA) Only.

COVID-19 TEST

1 Test

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North Industrial Park,

Xiamen, Fujian, 361021, P.R.China.

Email: support@bosoncovt.com

www.bosoncovt.com

Contents: 

1x SARS-CoV-2 Antigen Test Card

1x Sterilized Swab

1x Extraction Buffer Tube

1x Quick Reference Instructions

Tube Holder

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets

 before or after use.

• For ages 2 to 13, an adult must collect and test the

 anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past 

 or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial (repeat) 

 testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

UDI

.fda.gov/covid-tests visit: http://www COVID-19 diagnostic tests, please 

For information about current expiration dates for at-home OTC 
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only. Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

COVID-19 TEST

2 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North Industrial Park, 

Xiamen, Fujian, 361021, P.R.China.

Email: support@bosoncovt.com

www.bosoncovt.com

Contents: 

2x SARS-CoV-2 Antigen Test Card

2x Sterilized Swab

2x Extraction Buffer Tube

1x Quick Reference Instructions

Tube Holder

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets

 before or after use.

• For ages 2 to 13, an adult must collect and test the

 anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past 

 or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial (repeat) 

 testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests. 

UDI

.fda.gov/covid-tests COVID-19 diagnostic tests, please visit: http://www

For information about current expiration dates for at-home OTC 
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

COVID-19 TEST

4 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

4x SARS-CoV-2 Antigen Test Card

4x Sterilized Swab

4x Extraction Buffer Tube

1x Tube Holder

1x Quick Reference Instructions

UDI

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial (repeat) 

 testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

• Items necessary to use the kit,

but not provided:

- Timer

• For symbol glossary, refer to 

Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components 

away from children and pets 

before or after use.

• For ages 2 to 13, an adult must collect

and test the anterior nares specimen.

Xiamen Boson Biotech Co., Ltd.

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, 

Fujian, 361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

COVID-19 TEST

5 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

5x SARS-CoV-2 Antigen Test Card

5x Sterilized Swab

5x Extraction Buffer Tube

1x Tube Holder

1x Quick Reference Instructions

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial (repeat) 

 testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

UDI

• Items necessary to use the kit,

but not provided:

- Timer

• For symbol glossary, refer to 

Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components

away from children and pets 

before or after use.

• For ages 2 to 13, an adult must collect

 and test the anterior nares specimen.

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, 

Fujian, 361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

XXXXXXXX YYYY-MM-DD

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

COVID-19 TEST

8 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

8x SARS-CoV-2 Antigen Test Card

8x Sterilized Swab

8x Extraction Buffer Tube

2x Tube Holder

2x Quick Reference Instructions

UDI

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets before or after use.

• For ages 2 to 13, an adult must collect and test the anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or 

 pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial 

 (repeat) testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based 

 molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, Fujian, 

361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

XXXXXXXX YYYY-MM-DD

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

COVID-19 TEST

10 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

10x SARS-CoV-2 Antigen Test Card

10x Sterilized Swab

10x Extraction Buffer Tube

2x Tube Holder

2x Quick Reference Instructions

UDI

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets before or after use.

• For ages 2 to 13, an adult must collect and test the anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or 

 pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial 

 (repeat) testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based 

 molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, Fujian, 

361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

XXXXXXXX YYYY-MM-DD
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only.

Results in 15 minutes For Use Under an Emergency Use Authorization (EUA) Only.

COVID-19 TEST

20 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

20x SARS-CoV-2 Antigen Test Card

20x Sterilized Swab

20x Extraction Buffer Tube

5x Tube Holder

5x Quick Reference Instructions

UDI

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets before or after use.

• For ages 2 to 13, an adult must collect and test the anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or 

 pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial 

 (repeat) testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based 

 molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, Fujian, 

361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

XXXXXXXX YYYY-MM-DD

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests
Rapid SARS-CoV-2 Antigen Test Card

Home Test

For the rapid qualitative determination of SARS-CoV-2 antigen 

in anterior nasal swab specimens. 

For in vitro Diagnostic Use Only. Results in 15 For Use Under an Emergency Use Authorization (EUA) Only. minutes

40 Tests

Need help? Contact us at support@bosoncovt.com or call +1-800-689-7794. Ages 2 and up

Contents: 

40x SARS-CoV-2 Antigen Test Card

40x Sterilized Swab

40x Extraction Buffer Tube

5x Tube Holder

5x Quick Reference Instructions

UDI

• Items necessary to use the kit, but not provided:

 - Timer

• For symbol glossary, refer to Instructions for Use.

• Read all instructions carefully.

• Keep testing kit and components away from children and pets before or after use.

• For ages 2 to 13, an adult must collect and test the anterior nares specimen.

• This test does NOT determine if you had COVID-19 in the past or if you have immunity. 

• In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA.

• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or 

 pathogens.

• The emergency use of the product is only authorized for the duration of the declaration that circumstances exist

 justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under

 Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is

 terminated or authorization is revoked sooner.

• Determining a negative result requires multiple tests. You may need to purchase additional tests to perform serial 

 (repeat) testing. This test is more likely to give you a false negative result when you have COVID-19 than a lab-based 

 molecular test.

• The Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of

 nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal (nares) swabs from individuals. The test is authorized for 

 individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other 

 epidemiological reasons to suspect COVID-19. For symptomatic individuals, the test is authorized for use at least twice 

 over three days with at least 48 hours between tests. For asymptomatic individuals, the test is authorized for use at least 

 three times over five days with at least 48 hours between tests.

Xiamen Boson Biotech Co., Ltd. 

90-94 Tianfeng Road, Jimei North 

Industrial Park, Xiamen, Fujian, 

361021, P.R.China.

Email: support@bosoncovt.com 

www.bosoncovt.com

For information about current expiration dates for at-home OTC 

COVID-19 diagnostic tests, please visit: http://www.fda.gov/covid-tests